39 results about "Diabetes type i" patented technology

The present invention provides novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and / or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular alcohol disorder, drug abuse, growth retardation, cachexia, short-, medium-, and / or long term regulation of energy balance, short-, medium-, and / or long term regulation (stimulation and / or inhibition) of food intake, intake of rewarding food, adipogenesis, adiposity and / or obesity, body weight gain and / or reduction, diabetes, diabetes type I, diabetes type II, tumor cell proliferation, inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and / or gastrectomy (ghrelin replacement therapy).

The present invention is related to substituted methylene amide derivatives of formula (I) and use thereof for the treatment and / or prevention of metabolic disorders mediated by insulin resistance or pyperglycemia, comprising diabetes type I and / or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of substituted methylene amide derivatives of formula (I) to modulate, notably to inhibit the activity of PTPs. Also the present invention relates to a method of treating diabetes type II, obesity and to regulate the appetite of mammals. The present invention is furthermore related to novel substituted methylene amide derivatives and method of preparation thereof. Formula (I).

The invention discloses novel liquid medicine capable of treating cancer and having many other effects. The novel liquid medicine is prepared by using disodium hydrogen phosphate, carbonized hair andwater according to a certain proportion. The novel liquid medicine has the advantages that the new liquid medicine can be intermittently taken by cancer patients for a long time to treat cancer and prevent massive hemorrhage caused by tissue wounds formed after the cancer is dissolved, can be taken by patients with diabetes type I to inhibit the complication of the diabetes type I, can be taken bypatients with diabetes type II to lower blood sugar concentration, can be taken by hypertension patients to lower blood pressure, can be taken by hypotension patients to increase blood pressure, canbe taken by patients who have a cold to inhibit cold viruses, can be taken by patients with in-vivo herpes viruses and hepatitis B viruses to inhibit the herpes viruses and hepatitis B viruses, and can treat various other chronic diseases; the novel liquid medicine can also be intermittently taken by common people to achieve a healthcare effect, and the people who take the liquid medicine can havephysical and psychological health and pleasure and can be rejuvenated; the people who begin taking the liquid medicine need to be guided by staff with professional knowledge and skills and can take the liquid medicine by themselves after they master the main points; the effective liquid medicine is prepared on the basis of the scientific theoretical knowledge of the inventor and through constantmassive interest observation, logical highly-initiative analysis, judgment and reasoning, self-trial and trials on other people and constant improvement by the inventor, and the novel liquid medicineis an updated and original invention of the inventor.